TAC01-CLDN18.2

TAC01-CLDN18.2 (TAC01) is a TCR-T cell therapy developed by Triumvira Immunologics. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: A genetically engineered autologous T-cell therapy using a T-cell receptor Antigen Coupler (TAC) that directs T cells to CLDN18.2-expressing tumour cells and, once engaged, activates the T cells via the endogenous T-cell receptor. ClinicalTrials.gov describes the intervention as: TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05862324, plans to enrol 113 participants with primary completion expected 2027-08-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.